Monte Rosa Therapeutics (GLUE) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Income towards Parent Company fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Income towards Parent Company stood at -$27.1 million for Q3 2025, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Income towards Parent Company peaked at $46.9 million during Q1 2025, and registered a low of -$35.2 million during Q2 2023.
- In the last 3 years, Monte Rosa Therapeutics' Income towards Parent Company had a median value of -$30.3 million in 2024 and averaged -$18.2 million.
- Data for Monte Rosa Therapeutics' Income towards Parent Company shows a peak YoY increase of 24658.43% (in 2025) and a maximum YoY decrease of 1350.43% (in 2025) over the last 5 years.
- Monte Rosa Therapeutics' Income towards Parent Company (Quarter) stood at -$33.3 million in 2023, then surged by 140.32% to $13.4 million in 2024, then tumbled by 301.99% to -$27.1 million in 2025.
- Its Income towards Parent Company was -$27.1 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $46.9 million in Q1 2025.